Cassady Schiller Wealth Management LLC Reduces Position in Pfizer Inc. (NYSE:PFE)

Cassady Schiller Wealth Management LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 28.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,784 shares of the biopharmaceutical company’s stock after selling 1,133 shares during the quarter. Cassady Schiller Wealth Management LLC’s holdings in Pfizer were worth $74,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of PFE. Pitti Group Wealth Management LLC purchased a new position in shares of Pfizer during the 4th quarter valued at $375,000. Cibc World Markets Corp lifted its stake in shares of Pfizer by 17.3% during the 4th quarter. Cibc World Markets Corp now owns 902,242 shares of the biopharmaceutical company’s stock valued at $23,936,000 after buying an additional 133,084 shares in the last quarter. Creative Financial Designs Inc. ADV lifted its stake in shares of Pfizer by 4.7% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 44,882 shares of the biopharmaceutical company’s stock valued at $1,191,000 after buying an additional 2,023 shares in the last quarter. IMG Wealth Management Inc. purchased a new position in shares of Pfizer during the 4th quarter valued at $76,000. Finally, SlateStone Wealth LLC lifted its stake in shares of Pfizer by 5.7% during the 4th quarter. SlateStone Wealth LLC now owns 9,497 shares of the biopharmaceutical company’s stock valued at $252,000 after buying an additional 508 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $25.74 on Monday. The company has a market capitalization of $145.85 billion, a price-to-earnings ratio of 18.25, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The firm’s 50-day moving average is $26.24 and its 200 day moving average is $27.12. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s revenue was up 24.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.10 EPS. Research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of analyst reports. Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Bank of America reiterated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Wednesday, March 12th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.